ABIVAX signed an agreement with The Finlay Institute in Havana, Cuba, on Wednesday to commercialize vaccines against typhoid, meningococcus and leptospirosis in Asian and Latin American markets.
ABIVAX is a European clinical-stage biopharmaceutical company that has exclusive distribution rights for vax-TyVi, VA-MENGOC-BC and vax-SPIRAL.
"Today's agreement with The Finlay Institute is a further step in ABIVAX' strategy to become a global leader in the anti-virals and vaccines, and thus protect a large number of people from these serious and potentially life threatening infectious diseases,” Dr. Hartmut Ehrlich, CEO of ABIVAX, said. “We intend to leverage this deal by creating a strong distribution network in Asia and Latin America that will not only drive the sales of these competitive vaccine products but also products such as ABX203, which we currently have under development."
ABIVAX will market the vaccines in India, Indonesia, the Philippines, Brazil, Mexico and Uruguay.
"We are delighted to be working with ABIVAX,” Dr. Daniel Cardoso, of the Finlay Institute, said. “We have been impressed with their commitment to Cuba and our leading position in life sciences. We are confident that their experienced management team will be able to generate significant sales in Asia and Latin America from our proven vaccines against typhoid, meningococcus and leptospirosis, three major health care problems in these regions."